anti-TIGIT bispecific

AGEN1777 with expected IND filing by year end – a first-in-class TIGIT bispecific which targets a major inhibitory receptor expressed on T and NK cells to improve anti-tumor activity.

TIGIT is a negative regulator of innate and adaptive immune responses.

IND filing is expected by end of 2020.